A medication initially designed for a rare condition may enhance the survival rates of individuals suffering from an aggressive variant of ovarian cancer, as indicated by findings from a recent clinical trial.<\/p>\n
Platinum-resistant ovarian cancer is characterized by disease progression occurring within six months following the commencement of platinum-based chemotherapy. This chemotherapy approach differs from others by utilizing platinum-containing compounds to inhibit the division of cancer cells.<\/p>\n
Typically, patients diagnosed with platinum-resistant ovarian cancer have a bleak prognosis, with an average life expectancy of only one year after diagnosis, and they face limited treatment alternatives.<\/p>\n
A study featured in the Lancet evaluated data from 381 individuals with platinum-resistant ovarian cancer. Participants were administered either standard treatment or relacorilant, an oral medication used for Cushing’s syndrome, a disorder stemming from excessive cortisol levels.<\/p>\n
After an average follow-up duration of two years, results revealed a 35% decrease in mortality risk for patients receiving relacorilant in comparison to those undergoing standard care. On average, individuals in the relacorilant cohort lived four months longer than their counterparts in the control group.<\/p>\n
The researchers concluded that these outcomes indicate the potential of relacorilant to become a new standard treatment for patients battling platinum-resistant ovarian cancer.<\/p>\n
In a different study involving 643 patients with platinum-resistant ovarian cancer, those treated with pembrolizumab in conjunction with standard care had an average survival of 17.7 months, compared to 14 months for patients receiving only standard care. Pembrolizumab is an immunotherapy agent that enhances the immune system’s ability to target and destroy cancer cells.<\/p>\n
Ovarian cancer ranks as the sixth most prevalent cancer among women in the UK, with approximately 7,600 new diagnoses each year. It constitutes about 4% of all new cancer cases in women, leading to around 3,900 fatalities annually.<\/p>\n
Both clinical trials are currently in phase 3 and require additional testing before they can receive approval in the UK. Nevertheless, relacorilant and pembrolizumab have already been authorized by the Food and Drug Administration in the United States for treating platinum-resistant ovarian cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"
A medication initially designed for a rare condition may enhance the survival rates of individuals suffering from an aggressive variant of ovarian cancer, as indicated by findings from a recent clinical trial. Platinum-resistant ovarian cancer is characterized by disease progression occurring within six months following the commencement of platinum-based chemotherapy. This chemotherapy approach differs from […]<\/p>\n","protected":false},"author":2,"featured_media":6853,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[725,1652,695,1399,1650,175,99,88,1651],"tags":[],"class_list":["post-6854","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uk-cancer","category-uk-cancer-research","category-uk-health","category-uk-medical-research","category-uk-ovarian-cancer","category-uk-science","category-uk-society","category-uk","category-uk-women-s-health"],"yoast_head":"\n